Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Finally! Shire And Baxalta Sign $32bn Deal To Form Largest Rare Disease Company

This article was originally published in Scrip

Executive Summary

Shire plc and Baxalta Incorporated have confirmed they are to merge. The combined company, which will be 34% owned by Baxalta shareholders, will be "the partner of choice in rare diseases," claimed Shire CEO Flemming Ornskov.

You may also be interested in...



Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases

Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.

Takeda/Shire Deal Stands Fifth Largest In Biopharma M&A

The $62.4bn price tag for Takeda’s acquisition of Shire is topped globally only by the Pfizer take-outs of Warner-Lambert and Wyeth, the merger that created GlaxoSmithKline, and Actavis’ purchase of Allergan.

1Q Pharma Results Preview: Merck, Pfizer, Gilead, Novo Nordisk, Shire, Allergan, Teva

Part two of Scrip's preview of first quarter earnings: Recent launches, pricing strategies and biosimilar competition will be key themes as top-tier pharmaceutical companies continue to report first quarter performance.

Related Content

Topics

UsernamePublicRestriction

Register

SC064175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel